With the approval of effective vaccines (e.g. Pfizer, Moderna) and the potential introduction of several others (e.g. AstraZeneca), many investors are currently positioning their portfolios for the potential of an increasingly open economy. To get a sense of which stocks investors have focused on since the November 9th announcement of the first effective vaccine by Pfizer, we identified the top performing stocks (65% gain or more) between November 6, 2020 and January 12, 2021. The following table is limited to companies with a market cap of over $10 billion. The resulting list contains 19 stocks that have gained an average of 90% over the past two-plus months despite the unprecedented economic disruptions currently facing the world.
Best Vaccine Rally Stocks Table Description: The following table includes and can be sorted on: company name, market cap, dividend yield, intraday stock price, and the intraday stock price percent change. This live table is updated throughout the trading day. Don’t miss out on important revisions to our Best Vaccine Rally Stocks list. Get our free Dogs of the Dow Newsletter.
Best Vaccine Rally Stocks FAQ
Does Pfizer pay dividends?
Yes, Pfizer pays a dividend – with a dividend yield above 4%.
Which vaccines are currently available in the US?
Pfizer’s and Moderna’s COVID-19 vaccines are currently the only two available in the U.S.
Which companies are working on a COVID-19 vaccine?
Publicly traded U.S. companies working on COVID-19 vaccines are: AbbVie, Altimmune, Applied DNA Sciences, AstraZeneca, BioNTech & Pfizer, CureVac, Dynavax Technologies, GlaxoSmithKline, Heat Biologics, Inovio Pharmaceuticals, Johnson & Johnson, Merck, Moderna, Novavax, Sanofi, Vaxart & Emergent BioSolutions, and Vir Biotechnology & Biogen.
Who did Pfizer partner with on the COVID-19 vaccine?
Pfizer partnered with BioNTech, a German drugmaker, to develop their COVID-19 vaccine.